Bonesupport Holding Ab · OMXSTO:BONEX
Bonesupport Holding Ab — Investor Presentation (May 2020)
11 slides from Bonesupport Holding Ab's investor presentation, May 27, 2020
Slide 1: BONESUPPORT Investor presentation: Update following direct share issue 2020
BONESUPPORT Investor presentation Update following direct share issue 2020 May 27th
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: BONESUPPORT has carried out a directed share issue with proceeds of SEK 378 million
BONESUPPORT has carried out a directed share issue and is hereby provided with proceeds of SEK 378 million • BONESUPPORT Holding AB (publ) has, with the support of the authorization from the Annual General Meeting on 19 May 2020, resolved on a directed share issue of 10 500 000 ordinary shares at a
Slide 4: Capital raise 2020 - Scale up of proven business model
Capital raise 2020 - Scale up of proven business model Growth acceleration lever: Amount: COMMERCIALIZATION ~70% 1 US market introduction and penetration of CERAMENT G 2 Continued market investments in Europe 3 Regulatory approval new markets 4 Manufacturing improvements OPERATIONAL, RESEARCH & DEVE
Slide 5: US: Planning for early 2021 launch of CERAMENT G
US: Planning for early 2021 launch of CERAMENT G Background ✓ Distribution relationship with Zimmer Biomet terminated by BONESUPPORT in May 2018, with non-exclusivity ending May 2019. ✓ Established 40 independent distributors with 500 sales reps, active since Nov 1st 2018 ✓ Excellent traction in win
Slide 6: Large market opportunity for CERAMENT G in the US
Large market opportunity for CERAMENT G in the US • The US market for bone grafts for infected procedures is valued at USD 100m, • CERAMENT G, given approval, will be the first ever synthetic bone graft with antibiotics on the US market • In mid-March, the FDA assigned CERAMENT G as “Breakthrough De
Slide 7: EUROW: Sales penetration and sales expansion
EUROW: Sales penetration and sales expansion Background ✓ Sales of antibiotic eluting CERAMENT since 2014 ✓ Direct sales (employed sales reps) in Sweden, Denmark, UK, Germany and Switzerland ✓ Significantly under dimensioned sales team up until late 2018 and very low level of sales penetration in la
Slide 8: EUROW: Sales penetration and sales expansion
EUROW: Sales penetration and sales expansion • 86% of sales in EUROW is made from direct markets • Up until early 2018 BONESUPPORT had 12 direct sales reps. From 2018 to 2020 an additional 13 sales reps were hired • Penetration with university clinics are high. Ambassador users from these clinics wi
Slide 9: Operational, Research & Development
OPERATIONAL, RESEARCH & DEVELOPMENT Manufacturing and Supply Improvement Program Active R&D program CERAMENT + Short and mid term improvements to bring CERAMENT + DBM Bisphosphonate (BP) automatization and increase capacity Inhibits osteoclasts and attracts Osteoconductive and Mode of action: osteob
Slide 10: Capital raise to secure effective market penetration in the US, Europe and new markets
Capital raise to secure effective market penetration in the US, Europe and new markets, to pursue large untapped potential Expanding the platform for an accelerated growth journey • Preparing for market introduction of CERAMENT G in the US - De Novo application – Expected approval in late 2020 for b
Slide 11: CERAMENT Value generating milestones and roadmap
CERAMENT® Value generating milestones and roadmap March 2020 Q3 2020 Q4 2020 Q4 2021 May 20th Zimmer FDA designated CERAMENT G CERAMENT® G CERAMENT® G Biomet ceases to CERAMENT G as Potential Market Australia Launch PMA application sell CERAMENT “Breakthrough device” approval –under review- 2019 202
Bonesupport Holding — Investor Presentation (May 2020) on 6ix